Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Next Previous
Search
Trial Profile

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BEAM 302 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Beam Therapeutics

    • Most Recent Events

    • 05 Apr 2025 According to Beam Therapeutics media release, company recently announced the clearance of its investigational drug application (IND) for BEAM-302 by the United States (U.S.) Food and Drug Administration (FDA), enabling the company to activate sites in the U.S. for its ongoing Phase 1/2 trial.
    • 05 Apr 2025 Results presented in a Beam Therapeutics media release
    • 05 Apr 2025 According to Beam Therapeutics media release, additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress, taking place Apr 4-5, 2025, in Lisbon, Portugal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top